Examining neuroblastoma patient datasets from the SEQC cohort (GEO: GSE49711; ref. 28) and the NCI TARGET cohort (29), we found that ATF5 expression (Fig. 1A) was significantly higher in MYCN-amplified (MNA) tumors than in either high-risk MYCN-non-amplified (HR_NA) tumors (SEQC cohort P = 1.22E-05; TARGET cohort P = 7.64E-04) or stage 1 low-risk (LR) tumors (SEQC cohort P  =  7.27E-23, TARGET cohort P  =  4.85E-5). This evidence concerns the gene ATF5 and neuroblastoma.